ERDRP-0519

ERDRP-0519
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 2-methyl-N-[4-[(2S)-2-(2-morpholin-4-ylethyl)piperidin-1-yl]sulfonylphenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide;
CAS Number	1374006-96-8 ;
PubChem CID	57521469;
ChemSpider	28514843;
Chemical and physical data
Formula	C23H30F3N5O4S
Molar mass	529.574 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1c(cc(n1)C(F)(F)F)C(=O)Nc2ccc(cc2)S(=O)(=O)N3CCCC[C@H]3CCN4CCOCC4;
	InChI InChI=1S/C23H30F3N5O4S/c1-29-20(16-21(28-29)23(24,25)26)22(32)27-17-5-7-19(8-6-17)36(33,34)31-10-3-2-4-18(31)9-11-30-12-14-35-15-13-30/h5-8,16,18H,2-4,9-15H2,1H3,(H,27,32)/t18-/m0/s1; Key:JVZHTUQIMBYDSX-SFHVURJKSA-N;

ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection.[1][2]

History

The research was done at Georgia State University and the Paul Ehrlich Institute.[3]

References

White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK (2007). "Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.
Krumm, S. A.; Yan, D.; Hovingh, E. S.; Evers, T. J.; Enkirch, T.; Reddy, G. P.; Sun, A.; Saindane, M. T.; Arrendale, R. F.; Painter, G.; Liotta, D. C.; Natchus, M. G.; von Messling, V.; Plemper, R. K. (2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMC 4080709. PMID 24739760.
Grush, Loren (2015-03-24). "New oral drug can stop measles infection before symptoms begin". Fox News. Retrieved 2020-11-18.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK (2007). "Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.

[2] Krumm, S. A.; Yan, D.; Hovingh, E. S.; Evers, T. J.; Enkirch, T.; Reddy, G. P.; Sun, A.; Saindane, M. T.; Arrendale, R. F.; Painter, G.; Liotta, D. C.; Natchus, M. G.; von Messling, V.; Plemper, R. K. (2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMC 4080709. PMID 24739760.

[3] Grush, Loren (2015-03-24). "New oral drug can stop measles infection before symptoms begin". Fox News. Retrieved 2020-11-18.

ERDRP-0519

History

See also

References